NASDAQ
Prelude Therapeutics Incorporated (PRLD)
♥ 513 Thanks from members
Prelude Therapeutics (PRLD) exhibits a polarized market profile, balancing a 500% twelve-month rally and a newly established Incyte revenue stream against a risky, early-stage pipeline and historic program contractions.